Financial Daily from THE HINDU group of publications
Friday, Aug 19, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Announcements


Lupin gets USFDA nod

Our Bureau

MUMBAI: Lupin Ltd on Thursday said that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Cephalexin for Oral Suspension USP, 125 mg/5 ml and 250 mg/5 ml.

"We have identified cephalosporins as one of our focus areas for the US market.

The approval for Cephalexin will further boost our product basket. Given our leadership position in Cephalexin, we believe we will be able to drive value in the marketplace through forward-integration into the finished product,'' a press release said quoting Lupin's Chairman, Dr Desh Bandhu Gupta.

This is the company's sixth ANDA approved by the USFDA. Earlier it had received approvals for Ceftriaxone for injection, Cefotaxime for injection, Cefuroxime Axctil tablets and Cefixime tablets and oral suspension.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
ONGC begins salvage operations at Bombay High


Tata Motors launches 2 luxury variants of Indigo
BHPV gets Rs 47-cr order
Suven in talks with 3 US cos
Lupin gets USFDA nod
Pennar Steel warrants issue
Oudh Sugar to pay 25 pc dividend
Tata Steel vs POSCO - A tale of two MoUs
Cabinet seeks more details on KRL merger with BPCL
Tatas to acquire UK co Incat for Rs 416 cr
ONGC not keen on Govt's merger proposal for MRPL
Fidelity acquires IVRCL shares
Yamaha plans second wholly-owned subsidiary — To trade in two-wheelers and parts
Greenply plans Rs 80-cr plant in Uttaranchal
Lanka IOC plans mid-sea bunkering point off Trincomalee
Analysts predict tough quarters for HLL
Sundram Fasteners' China unit doing Rs 1-cr biz a month


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line